## **CLINICAL PATHWAY:**

# **Venous Thromboembolism Prevention**

THIS PATHWAY SERVES AS A GUIDE AND DOES NOT REPLACE CLINICAL

If patient develops a VTE while in the hospital, exit pathway and treat in consultation with hematology

### <sup>1</sup>Degree of Mobility

- Baseline: Non-ambulatory at baseline OR ambulatory at baseline and can ambulate distance of 50 feet, 3x day
- Altered: Ambulatory at baseline and unable to ambulate freely, ie, bathroom privileges, pivot to chair

## <sup>3</sup>VTE Risk Factors

#### Acute conditions

- Critically ill (admitted to PICU)
- Acute systemic infection or inflammation Central venous catheter (CVC)
- Active cancer/malignancy
- Pregnancy
- Surgery within the past 30 days
- Burns with total body surface area >50%
- Major trauma requiring admission to PICU Colonic inflammatory bowel disease (IBD)
- within the first year of diagnosis and on steroids (in addition to chronic IBD diagnosis as risk factor)

### **Chronic conditions**


- Obesity (<18 years: BMI >95<sup>th</sup> percentile for age, >18 years: BMI >30)
- Sickle cell disease
- Inflammatory disorder (eg, IBD, systemic lupus erythematosus (SLE))
- Protein losing disorder (eg, nephrotic syndrome, protein losing enteropathy (PLE), chylous effusion)
- Asparaginase or estrogen-containing medications (eg, hormonal therapy)
- Thrombophilia (factor V Leiden, prothrombin gene mutation, inherited deficiency of protein S, C, or antithrombin)

- Patient history of VTE/pulmonary embolism
- Family history of VTE in 1st degree relative

### <sup>4</sup>Inflammatory bowel disease (IBD) considerations

- Acute and chronic conditions count as separate risk factors
- Expected bloody diarrhea is not a contraindication to pharmacologic prophylaxis

Inclusion Criteria: All patients placed under observation or admitted to inpatient unit Exclusion Criteria: Known presence of venous thromboembolism (VTE)



- RN to perform VTE risk assessment within 24 hours of admission and then every 2 days
  - RN to document risk level in Epic

Low Risk

Encourage highest degree of

mobility at least 3x per day

mobility<sup>1</sup> with no risk

#### <sup>2</sup>High Risk **Moderate Risk**

- Impaired mobility<sup>1</sup> with ≥2 risk factors<sup>3</sup>; **or**
- MIS-C diagnosis; or Symptomatic COVID-19
- IBD patients with ≥1 additional risk factor(s) <sup>3,4</sup>


Encourage highest degree of mobility at

Mechanical prophylaxis with sequential compression devices (SCD) when in bed. if no contraindications (Appendix A)

Baseline mobility¹ with ≥1 risk

Impaired mobility with 0-1 risk

- Encourage highest degree of mobility at least 3x per day Mechanical prophylaxis with sequential compression devices (SCD) when in bed, if no contraindications (Appendix A)
- Pharmacologic prophylaxis with anticoagulation, if no contraindications (Appendix A)
  - Monitor for signs/symptoms of bleeding
  - If recent surgery, discuss with surgical team
  - Consider discussion with hematology
  - Enoxaparin (Lovenox) dosing <90kg and BMI<35kg/m<sup>2</sup> - < 18 years old
    - - < 40kg: enoxaparin 0.5mg/kg/dose SQ q12 hours 40-89.9kg: enoxaparin 40mg SQ daily
    - -> 18 years old
      - < 50kg: enoxaparin 0.5 mg/kg/dose SQ daily 50-89.9 kg: enoxaparin 40mg SQ daily
  - Enoxaparin (Lovenox) dosing for ≥90kg OR BMI≥35kg/m Enoxaparin 0.5mg/kg/dose SQ q12 hours (max dose 40mg SQ q12 hours)
- VTE risk assessment continues every 2 days until patient is discharged





## **CLINICAL PATHWAY:**

## **Venous Thromboembolism Prevention**

Appendix A: Contraindications to Mechanical and Pharmacologic Venous Thromboembolism Prophylaxis

THIS PATHWAY SERVES AS A GUIDE AND DOES NOT REPLACE CLINICAL JUDGMENT.

## **Contraindications to sequential compression device (SCD):**

- Suspected or existing VTE (use graded compression stockings)
- Acute fracture of extremity (use device on unaffected extremity)
- Skin conditions affecting extremity (e.g., dermatitis, burn)
- PIV in extremity (use device on unaffected extremity)
- Lower extremity conditions that result in significant pain with compression (e.g., solid tumor, vaso-occlusive episode in sickle cell disease)
- Unable to achieve correct fit due to patient size

# **Contraindications to pharmacologic prophylaxis:**

## **ABSOLUTE**

- Intracranial hemorrhage
- Congenital or acquired bleeding disorder
- Platelet count unable to be sustained >50,000m3
- Uncorrected coagulopathy
- Acute stroke or brain ischemia
- Allergy to heparin or enoxaparin [e.g., hx of heparin induced thrombocytopenia (HIT)]
- Ongoing and uncontrolled bleeding (exceptions include bloody diarrhea in inflammatory bowel disease flare; discuss with GI team)

### **RELATIVE**

- Intracranial mass
- Lumbar puncture or epidural catheter placement within last 4 hours or removal in prior
- Uncontrolled severe hypertension
- Anticipated invasive procedure in next 24 hours
- Spine surgery or injury
- Suspected or known paraspinal hematoma

